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ABSTRACT
Introduction: Preoperative functional capacity is
considered an important risk factor for cardiovascular
and other complications of major non-cardiac surgery.
Nonetheless, the usual approach for estimating
preoperative functional capacity, namely doctors’
subjective assessment, may not accurately predict
postoperative morbidity or mortality. 3 possible
alternatives are cardiopulmonary exercise testing; the
Duke Activity Status Index, a standardised
questionnaire for estimating functional capacity; and
the serum concentration of N-terminal pro-B-type
natriuretic peptide (NT pro-BNP), a biomarker for heart
failure and cardiac ischaemia.
Methods and analysis: The Measurement of
Exercise Tolerance before Surgery (METS) Study is a
multicentre prospective cohort study of patients
undergoing major elective non-cardiac surgery at 25
participating study sites in Australia, Canada, New
Zealand and the UK. We aim to recruit 1723
participants. Prior to surgery, participants undergo
symptom-limited cardiopulmonary exercise testing on a
cycle ergometer, complete the Duke Activity Status
Index questionnaire, undergo blood sampling to
measure serum NT pro-BNP concentration and have
their functional capacity subjectively assessed by their
responsible doctors. Participants are followed for
1 year after surgery to assess vital status, postoperative
complications and general health utilities. The primary
outcome is all-cause death or non-fatal myocardial
infarction within 30 days after surgery, and the
secondary outcome is all-cause death within 1 year
after surgery. Both receiver-operating-characteristic
curve methods and risk reclassification table methods
will be used to compare the prognostic accuracy of
preoperative subjective assessment, peak oxygen
consumption during cardiopulmonary exercise testing,
Duke Activity Status Index scores and serum NT pro-
BNP concentration.
Ethics and dissemination: The METS Study has
received research ethics board approval at all sites.
Participant recruitment began in March 2013, and 1-
year follow-up is expected to finish in 2016.
Publication of the results of the METS Study is
anticipated to occur in 2017.
INTRODUCTION
More than 300 million individuals undergo
major surgery worldwide every year, and
Strengths and limitations of this study
▪ A large generalisable sample of 1723 participants
at multiple centres worldwide will be used to
estimate the prognostic accuracy of cardiopul-
monary exercise testing, the Duke Activity Status
Index and the serum concentration of N-terminal
pro-B-type natriuretic peptide.
▪ The study involves detailed prospective follow-up
after surgery to ascertain survival, major compli-
cations and general health utilities.
▪ Participants, healthcare personnel and outcome
adjudicators are blinded to cardiopulmonary
exercise testing results, Duke Activity Status
Index scores and serum N-terminal pro-B-type
natriuretic peptide concentration, thereby facilitat-
ing unbiased estimates of their prognostic
accuracy.
▪ An important potential limitation is selection bias
introduced by individuals who meet eligibility cri-
teria, are theoretically capable of exercising, but
decline to participate in a research study of exer-
cise testing. Such non-participants may be sys-
tematically different due to possible higher
likelihood of having other markers of poor health
(eg, smoking).
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many are at risk for postoperative cardiovascular compli-
cations.1 2 Clinical practice guidelines recommend
preoperative risk stratiﬁcation as a component of any
strategy to prevent these complications.3 Risk-
stratiﬁcation algorithms proposed by several inter-
national guidelines emphasise the assessment of
preoperative ﬁtness or functional capacity.3 4 For
example, the current American College of Cardiology
and American Heart Association guidelines recommend
that patients be allowed to proceed directly to elective
major non-cardiac surgery if they are deemed capable of
more than four metabolic equivalents of activity without
symptoms.3 Preoperative functional capacity is also a ver-
satile measure of perioperative risk since it may stratify
risk for non-cardiovascular complications such as pneu-
monia, respiratory failure and infection.5–9
The current standard of care for assessing preopera-
tive functional capacity involves a doctor making a sub-
jective estimate after interviewing the patient. Previous
studies highlight potential limitations with this approach,
including poor accuracy when predicting death or com-
plications after non-cardiac surgery,10 11 as well as poor
agreement with validated measures of functional cap-
acity.12 These limitations point to the need for more
accurate alternatives to assess preoperative functional
capacity and, in turn, surgical outcomes. Three potential
options are cardiopulmonary exercise testing (CPET),
which is often considered to be the ‘gold standard’ non-
invasive assessment of functional capacity; the Duke
Activity Status Index (DASI),13 which is a standardised
questionnaire with demonstrated correlation to gold
standard measures of functional capacity; and the serum
concentration of N-terminal pro-B-type natriuretic
peptide (NT pro-BNP), which is biomarker for heart
failure or cardiac ischaemia.
CPET requires patients to undergo symptom-limited
incremental exercise on a bicycle or treadmill for 8–
12 min while undergoing continuous spirometry. Indices
of cardiorespiratory performance are simultaneously
measured, with the most common being peak oxygen
consumption (VO2 peak) and anaerobic threshold (AT).
Recent systematic reviews and individual studies largely
support preoperative CPET as a predictor of complica-
tions after surgery,14–16 but acknowledge important lim-
itations. For example, many prior studies have important
methodological problems. Speciﬁcally, very few studies
blinded caregivers or outcome adjudicators to CPET
results,17–19 thereby potentially biasing estimates of prog-
nostic accuracy in the vast majority of previous studies.20
In addition, many studies have limited generalisability
due to small sample sizes and single-centre designs. Thus,
despite the theoretical promise of CPET in the periopera-
tive setting, higher quality evidence remains needed to
conﬁrm its prognostic accuracy, identify patients who
warrant this expensive and specialised test, and provide a
robust argument for its wider implementation.
The DASI is a 12-item self-administered questionnaire
enquiring about activities of daily living. It has construct
and criterion validity as a measure of functional capacity
in surgical patients.21 22 No large study has evaluated the
prognostic accuracy of a preoperative DASI score for
predicting outcomes after surgery.
While no blood test can quantify functional capacity,
serum concentration of NT pro-BNP may indirectly fulﬁl
this role by serving as an integrated marker of cardiac
dysfunction, including myocardial stretch and ischae-
mia.23 24 Emerging data, which include several individ-
ual studies from our group as well as meta-analyses,25–29
have found preoperative NT pro-BNP concentrations to
have reasonable prognostic accuracy in predicting death
and cardiac complications after non-cardiac surgery.
To help develop improved methods to measure pre-
operative functional capacity and incorporate it into
overall surgical risk assessment, we are conducting the
Measurement of Exercise Tolerance before Surgery
(METS) Study. The main objectives of this multicentre
prospective cohort study are presented below.
Primary objective
To compare preoperative CPET to subjective assessment
for predicting death or non-fatal myocardial infarction
(MI) within 30 days after major elective non-cardiac
surgery.
Secondary objectives
1. To compare CPET to subjective assessment for pre-
dicting death within 1 year after major elective non-
cardiac surgery.
2. To compare preoperative DASI, NT pro-BNP, CPET
and subjective assessment for predicting death or
non-fatal MI within 30 days after non-cardiac surgery.
3. To compare preoperative DASI, NT pro-BNP, CPET
and subjective assessment for predicting death within
1 year after major elective non-cardiac surgery.
METHODS AND ANALYSIS
Study design
The METS Study is a multinational prospective cohort
study of 1723 patients undergoing major elective non-
cardiac surgery at participating centres in Australia,
Canada, New Zealand and the UK. The overall study
design is outlined in ﬁgure 1.
Participant eligibility criteria
Potential participants are recruited from the preopera-
tive assessment clinics or surgical wards of participating
sites. To be eligible to participate in the METS Study,
individuals must be aged 40 years or older, and sched-
uled to undergo elective non-cardiac surgery under
general and/or regional anaesthesia with a minimum of
an overnight hospital stay for medical reasons. In add-
ition, they must have one or more clinical risk factors
for perioperative cardiac complications or coronary
artery disease (table 1). Exclusion criteria are presented
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on box 1 and table 2. All participants provide informed
consent at time of recruitment to the study.
Preoperative cardiopulmonary exercise testing
During the period from study recruitment to 1 day
before surgery, participants undergo symptom-limited
incremental CPET on a computer-controlled, electro-
magnetically braked cycle ergometer, under physician
supervision and in accordance with published guide-
lines.30 Prior to CPET, each participant performs spirom-
etry with forced inspiratory and expiratory ﬂow volume
loops. The subsequent incremental exercise test takes 8–
Figure 1 Overall design of the METS Study. CPET, cardiopulmonary exercise test; DASI, Duke Activity Status Index; METS,
Measurement of Exercise Tolerance before Surgery; NT pro-BNP, N-terminal pro-B-type natriuretic peptide; VO2, oxygen
consumption.
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12 min to complete. It follows a preliminary 3 min
resting period, during which the participant sits on the
cycle ergometer while cardiovascular and respiratory
measurements are taken, and 3 min of unloaded cycling
(0 W) that serves a warm up. At testing sites where the
cycle ergometers cannot be set to 0 W, the unloaded
cycling phase is set at the minimum workload possible
on the local cycle ergometer. Pedalling resistance is then
increased progressively every minute using a ramped
protocol during which participants pedal at 60 revolu-
tions per minute. Typically, work rates are increased by
10 W per minute in untrained individuals, and by up to
20–30 W per minute in well-trained participants or those
that participate regularly in physical activity.
Participants exercise until they reach their limit of tol-
erance (ie, unable to pedal at 60 revolutions per minute
despite encouragement), stop for non-cardiopulmonary
reasons or are instructed to stop based on safety-based
termination criteria.30 Reasons for termination are docu-
mented for all tests. Participants undergo
breath-by-breath measurement of minute ventilation,
oxygen uptake and carbon dioxide production from
expired gas during the exercise test. In addition, heart
rate, blood pressure, three-lead ECG, arterial oxygen sat-
uration and rating of perceived exertion (modiﬁed Borg
scale) are measured.31 After the exercise test is stopped,
participants continue to pedal for a 5 min recovery
period, during which the work intensity is reduced to
20 W. During this recovery period, monitoring of heart
rate, blood pressure, ECG, oxygen consumption and
carbon dioxide production is continued.
The site investigator at each participating CPET
centre determines VO2 peak and AT using full-page
graphs of the plotted local CPET data. The VO2 peak is
deﬁned as the average oxygen consumption during the
last 20 s of the incremental phase of exercise before
attaining the limit of tolerance.32 The AT is determined
using the modiﬁed V-Slope method.33 If the AT is inde-
terminate based on this method alone, the ventilatory
equivalent method and excess carbon dioxide method
are applied sequentially until the AT is either measured
or classiﬁed as indeterminate.33 Participants, clinicians
and outcome adjudicators are blinded to all CPET
results, except if myocardial ischaemia or signiﬁcant
new arrhythmias occur during exercise, or spirometry
shows previously undiagnosed very severe obstructive
lung disease (forced expiratory volume in 1 s less than
30% predicted). In these cases, clinicians are informed
Table 1 Clinical risk factors required for inclusion in the METS Study*
Risk factor Definition
Intermediate-to-high risk
surgery
Intraperitoneal, intrathoracic or major vascular (suprainguinal or lower extremity vascular)
procedures
Coronary artery disease History of angina; myocardial infarction; positive exercise, nuclear or echocardiographic stress
test; resting wall motion abnormalities on echocardiogram; coronary angiography with
evidence of ≥50% vessel stenosis; or ECG with pathological Q-waves in two contiguous leads
Heart failure History of heart failure or diagnostic chest X-ray (ie, pulmonary vascular redistribution or
pulmonary oedema)
Cerebrovascular disease History of stroke or transient ischaemic attack; or imaging (CT or MRI) evidence of previous
stroke
Diabetes mellitus Requirement for insulin or oral hypoglycaemic therapy
Preoperative renal
insufficiency
Requirement for renal replacement therapy before surgery, or estimated glomerular filtration
rate† less than 60 mL/min/1.73 m2
Peripheral arterial disease History of peripheral arterial disease; ischaemic intermittent claudication; rest pain; lower limb
revascularisation procedure; peripheral arterial obstruction of ≥50% luminal diameter; or
resting ankle/arm systolic blood pressure ratio ≤0.90
Hypertension Physician diagnosis of hypertension
Smoker History of smoking within 1 year before surgery
Advanced age 70 years or older
*One or more of these risk factors must be present to meet the study eligibility criteria.
†Estimated using the MDRD Study equation.58
MDRD, Modification of Diet in Renal Disease; METS, Measurement of Exercise Tolerance before Surgery.
Box 1 Exclusion criteria for the Measurement of Exercise
Tolerance before Surgery (METS) Study
▸ At the time of approach for potential recruitment to study,
inadequate time to feasible complete cardiopulmonary exercise
testing (CPET) before surgery (defined as less than 24 h)
▸ Planned use of CPET for preoperative risk stratification inde-
pendent of METS study protocol
▸ Planned surgery exclusively performed by an endovascular
approach (eg, endovascular aortic aneurysm repair)
▸ Presence of an automated implantable cardioverter-defibrillator
▸ Known or suspected pregnancy
▸ Previous enrolment in the METS Study
▸ Active cardiac conditions,59 absolute contraindications to
CPET (American Thoracic Society and American College of
Chest Physicians guidelines)30 and conditions expected to pre-
clude CPET (eg, lower limb amputation, severe claudication)
▸ Systolic blood pressure ≥180 mm Hg and diastolic blood
pressure ≥100 mm Hg at the time of potential study
recruitment
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of these speciﬁc ﬁndings, but not the VO2 peak or AT
values.
Other estimates of preoperative functional capacity
Each participant undergoes three other assessments of
preoperative functional capacity. Subjective assessment
of the participant’s functional capacity is performed
either by the attending doctor in the preoperative assess-
ment clinic on the date of recruitment, or by the attend-
ing anaesthesiologist on the day of surgery. This estimate
is categorised as poor (less than 4 metabolic equiva-
lents), moderate (4–10 metabolic equivalents) or good
(more than 10 metabolic equivalents). In addition, the
DASI questionnaire is completed on the day of recruit-
ment. At any point between study recruitment and initi-
ation of surgery, a blood sample is drawn to measure the
serum concentration of NT pro-BNP. These samples are
initially stored at −70°C to −80°C in each study site, and
then sent for analysis at the core study laboratory, the
Clinical Biochemistry Laboratory at the Aberdeen Royal
Inﬁrmary (Aberdeen, UK). The NT pro-BNP samples
are analysed in batches using the Siemens Vista
immunoassay analyser (Siemens Healthcare Diagnostics
Ltd, Frimley, UK). Clinicians and outcome adjudicators
are blinded to DASI and NT pro-BNP results, while par-
ticipants are blinded to NT pro-BNP results.
Follow-up procedures
Research personnel follow the study participants daily
throughout their hospital stay. While participants remain
in hospital, follow-up procedures includes performance
of ECGs, the Postoperative Morbidity Survey34 35 and
blood sampling to measure troponin and creatinine con-
centrations. The ECGs and blood sampling are per-
formed daily for the ﬁrst 3 days after surgery, while the
Postoperative Morbidity Survey is administered on the
third and ﬁfth days after surgery. The speciﬁc troponin
assays used are the preferred assays at each participating
site. After hospital discharge, participants are contacted
again at 30 days and 1 year after surgery to ascertain
study-related outcomes, including vital status and health
utilities measured by the EuroQol EQ-5D.36
Outcome measures
The primary outcome is all-cause death or non-fatal MI
within 30 days after surgery. All potential MI events are
centrally adjudicated based on consensus-based deﬁni-
tions (table 3) by an Outcome Adjudication Committee
that is blinded to all CPET, DASI and NT pro-BNP
results.37 The secondary outcome is all-cause death
within 1 year after surgery. Postoperative follow-up also
includes ascertainment of other clinical events (table 3)
to help further explain any differing survival associated
with preoperative functional capacity.
Statistical analysis
Since the METS Study compares several tests for predict-
ing postoperative risk, the main statistical analyses will
only include individuals who undergo their planned sur-
geries. Nonetheless, characteristics and outcomes of
Table 2 Definitions of specific exclusion criteria in the METS Study
Active cardiac conditions59 Acute coronary syndrome: myocardial infarction within prior 30 days, unstable angina, or
severe angina (Canadian Cardiovascular Society class III or IV)
Decompensated heart failure (New York Heart Association functional Class IV), new onset
heart failure, or worsening heart failure
Significant arrhythmias: atrioventricular heart block (high grade, Mobitz II, third-degree);
symptomatic ventricular arrhythmias; supraventricular arrhythmias with uncontrolled
ventricular rate (ie, >100 bpm at rest); symptomatic bradycardia; or newly recognised
ventricular tachycardia
Severe valvular disease: severe aortic stenosis (mean pressure gradient >40 mm Hg, aortic
valve area <1.0 cm2 or symptomatic aortic stenosis); or symptomatic mitral stenosis
(progressive dyspnoea on exertion, exertional presyncope or heart failure)
Absolute contraindications to
CPET30
Recent acute myocardial infarction (3–5 days) or unstable angina
Uncontrolled arrhythmias causing symptoms or haemodynamic compromise
Syncope
Active endocarditis
Acute myocarditis or pericarditis
Symptomatic severe aortic stenosis
Uncontrolled heart failure or pulmonary oedema
Acute pulmonary embolus or pulmonary infarction
Thrombosis of lower extremities
Suspected dissecting aneurysm
Uncontrolled asthma or respiratory failure
Oxygen saturation at rest less than 85%
Acute non-cardiopulmonary disorder that may affect exercise performance or be aggravated
by exercise (ie, infection, renal failure, thyrotoxicosis)
Mental impairment leading to inability to cooperate
CPET, cardiopulmonary exercise testing; METS, Measurement of Exercise Tolerance before Surgery.
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Table 3 Definitions of outcomes and postoperative events
Outcome Definition
Myocardial infarction37 An elevation in serum troponin that both
▸ Exceeds the 99th centile of the normal reference population
▸ Exceeds the threshold at which the coefficient of variation for the assay is 10%
At least one of the following must be present:
▸ Clinical symptoms of ischaemia
▸ Typical ECG changes of ischaemia
▸ New pathological Q-waves on ECG
▸ Coronary artery intervention
▸ New (or presumed new) changes on echocardiography or radionuclide imaging
Myocardial injury1 An elevation in serum troponin that both
▸ Exceeds the 99th centile of the normal reference population
▸ Exceeds the threshold at which the coefficient of variation for the assay is 10%
Non-fatal cardiac arrest1 Successful resuscitation from documented (or presumed) ventricular fibrillation, sustained
ventricular tachycardia, asystole, or pulseless electrical activity
Heart failure1 Presence of both
▸ Clinical findings (ie, elevated jugular venous pressure, respiratory rales, crepitations, S3 heart
sounds)
▸ Radiological findings (ie, vascular redistribution, interstitial or frank pulmonary oedema)
Stroke1 New focal neurological deficit, suspected to vascular in origin, with signs/symptoms lasting ≥24 h
Transient ischaemic
attack
Transient focal neurological deficit that lasts less than 24 h and is thought to be vascular in origin
Respiratory failure60 Need for tracheal intubation and mechanical ventilation after patient has completed surgery, been
successful extubated, and breathing spontaneously for >1 h
Pneumonia1 Documented hypoxaemia (PaO2/FiO2 ratio ≤250 mm Hg) or fever (temperature >37.5°C) with
either:
1. Rales or dullness to percussion on chest examination and any of (i) new onset of purulent
sputum or change in sputum character; (ii) organism isolated from blood culture; or (iii)
pathogen isolated from transtracheal aspirate, bronchial brushing or biopsy
2. New or progressive infiltrate, consolidation, cavitation or pleural effusion on chest radiograph
and any of (1) criteria i, ii or iii above; (2) detection of virus or viral antigen in respiratory
secretions; (3) diagnostic antibody titres; or (4) histopathological evidence of pneumonia
Surgical site infection Physician diagnosis of surgical site infection during:
▸ Index hospitalisation
▸ Outpatient visit, hospital readmission or emergency room visit within 30 days after index surgery
Deep venous
thrombosis1
Any of the following during index hospitalisation:
1. Persistent intraluminal filling defect on contrast venography
2. One or more non-compressible venous segments on B mode compression ultrasonography
3. Clearly defined intraluminal filling defect on contrast-enhanced CT
Pulmonary embolism1 Any of the following during index hospitalisation:
1. High probability ventilation/perfusion lung scan
2. Intraluminal filling defect of segmental or larger artery on a helical CT scan
3. Intraluminal filling defect on pulmonary angiography
4. A positive diagnostic test for DVT (eg, positive compression ultrasound) plus low or
intermediate probability ventilation/perfusion lung scan, or non-diagnostic (subsegmental
defects or technically inadequate study) helical CT scan
Significant bleeding Blood loss with any of the following characteristics:
1. Results in drop in haemoglobin of 30 g/L or more
2. Leads to red cell transfusion or re-operation
3. Is considered to the cause of death
Postoperative
complications*
Severity of complications are classified (based on most severe events during the index
hospitalisation) as:
1. None
2. Mild: only temporary harm that does not require clinical treatment
3. Moderate: required clinical treatment but without significantly prolonged hospital stay. Does not
usually result in permanent harm and where this does occur, the harm does not cause
functional limitation
4. Severe—requires clinical treatment and results in significant prolongation of hospital stay and/or
permanent functional limitation
Continued
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individuals who do not undergo their planned surgeries
will still be captured and described separately. Two com-
plementary analyses are planned to account for partici-
pants who are not able to exercise enough to provide a
valid measurement of VO2 peak. Analyses will be per-
formed only after completion of 1-year follow-up for all
recruited participants.
The primary analysis includes individuals who success-
fully complete CPET by reaching their limit of tolerance
with a valid measurement of VO2 peak. Two sets of logis-
tic regression models will be used to separately model the
risks of (1) 30-day non-fatal MI or death and (2) 1-year
death. We will ﬁrst include only baseline clinical data (ie,
risk factors in the Revised Cardiac Risk Index),38 and
then, in sequential fashion, add in subjective assessment,
followed by VO2 peak to the model. The statistical signiﬁ-
cance of prognostic information from the additional pre-
dictors will be assessed based on the increase in log
likelihood of the ‘larger’ model. We will also determine
the area under the receiver-operating-characteristic
(ROC) curve of models with successively more predictors,
as well as models with only the individual exposure of
interest (eg, subjective assessment alone, or VO2 peak
alone).39 The difference in overall prognostic informa-
tion between models will be assessed by comparing the
area under the curve (AUC) of two ROC curves.40 We
have based our sample size calculation on the AUC
approach because it is commonly used in prognostic
studies, and requires less speculative parameter estimates
than other methods. Nonetheless, the test based on
improvement in AUC may be relatively insensitive,41 with
other methods offering more statistical power. We have
therefore opted for a more conservative sample size cal-
culation, but will use additional statistical approaches,
including the logistic regression likelihood test and net
reclassiﬁcation improvement statistic,42 for further signiﬁ-
cance testing. These same methods will also be used to
evaluate the additional prognostic information conveyed
by DASI or NT pro-BNP.
The secondary analysis will include all participants who
attempted CPET, regardless of whether a valid measure-
ment of VO2 peak was obtained. For this analysis, CPET
results will be categorised as (1) early termination for
safety reasons, (2) early termination for non-
cardiopulmonary reasons and (3) strata deﬁned by the
optimal VO2 peak cut-off points deﬁned in the primary
analysis. The same analytic approaches used in the
primary analysis will then be repeated while instead
expressing the results of CPET based on these
categories.
Sample size calculation
The sample size calculation is based on comparing the
AUC of ROC curves for CPET versus subjective assess-
ment with respect to predicting 30-day non-fatal MI or
death.39 40 Assuming an outcome event rate of 8%, a
poor-to-moderate AUC of 0.65 for subjective assess-
ment,11 43 a moderately good AUC of 0.75 for VO2
peak,43 and a conservative estimated correlation of 0.5
between VO2 peak and subjective assessment,
13 22 a
sample size of 1180 participants has 90% power to
detect this clinically relevant difference in AUC values
(two-sided α of 0.05). If the outcome event rate is
instead 6%, this sample size has 81% power to detect
the same difference. Based on studies that conducted
systematic postoperative surveillance of
intermediate-to-high risk patients undergoing non-
cardiac surgery,1 44 45 we anticipate the rate of 30-day
non-fatal MI or death to be 6–9%. This sample size of
1180 applies to the primary analysis, which is restricted
to individuals who undergo their planned non-cardiac
surgery and complete CPET with a valid measurement
of VO2 peak. Thus, this analysis does not necessarily
include all individuals who consent to participate in the
METS Study. For example, it does not include indivi-
duals who cannot exercise sufﬁciently for a valid meas-
urement of VO2 peak, or fail to attend their CPET
session due to unexpected rescheduling of planned sur-
geries. To account for up to 10% of recruited partici-
pants not being eligible for inclusion in the primary
analysis, the overall sample size was increased to 1312.
After recruiting half of the original planned sample
size, this sample size calculation was re-evaluated based
on two factors identiﬁed in the accumulating study data.
First, we found that about 20% of participants did not
either successfully complete CPET or undergo their
planned surgeries. Second, the event rate for the primary
outcome was approximately 5%. Based on this informa-
tion, the overall sample size was increased to 1723 parti-
cipants to account for up to 20% of recruited
individuals not being eligible for the primary analysis,
and a primary outcome event rate of 5%, while retaining
the power of 80%. Importantly, no data on the principal
exposures (ie, CPET results, DASI scores, NT pro-BNP
concentration) were considered during this sample size
re-estimation.
Table 3 Continued
Outcome Definition
5. Fatal—death from the complication
General health utilities36 Measured at study recruitment, 30 days after surgery and 1 year after surgery using the EuroQol
EQ-5D
*Severity of complications are classified based on scheme adapted from Clavien-Dindo classification system.61
DVT, deep vein thrombosis; FiO2, fractional inspired oxygen; PaO2, arterial oxygen tension.
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Study management and funding
The Applied Health Research Centre at St Michael’s
Hospital (Toronto, Ontario, Canada) is responsible for
the overall international coordination of the METS
Study. Two national coordinating centres also help liaise
with local investigators in speciﬁc countries, namely the
Royal London Hospital (London, UK) for the UK, and
the Alfred Hospital (Melbourne, Victoria, Australia) for
Australia and New Zealand. The study investigators par-
ticipating in the METS Study, as well as their respective
roles, are listed in the online supplementary data appen-
dix. All study data are captured with electronic case
record forms on a secure web-based database that was
developed using Medidata RAVE (Medidata Solutions
Inc, New York, New York, USA). The METS Study is
funded by peer-reviewed grants from the Canadian
Institutes of Health Research, Heart and Stroke
Foundation of Canada, Ontario Ministry of Health and
Long-Term Care, National Institute of Academic
Anaesthesia, UK Clinical Research Network, Australian
and New Zealand College of Anaesthetists, and Monash
University (Melbourne, Victoria, Australia).
Study status
Participant recruitment to the METS Study was started
in March 2013. The study involves 25 participating
centres in Australia, Canada, New Zealand and the UK.
Completion of 1-year follow-up period is anticipated for
late 2016.
Substudies
We have developed a formal process for investigators
within the research group to propose, design and lead
substudies based on the data collected from this large
international cohort of patients undergoing major elect-
ive non-cardiac surgery. Three substudies have already
been prespeciﬁed. The ﬁrst substudy will evaluate the
prognostic accuracy of AT as determined by site investi-
gators at each participating CPET centre. The second
substudy will evaluate the prognostic accuracy of VO2
peak and AT measurements that are centrally adjudi-
cated by a panel of three CPET experts. These experts
will remain blinded to initial assessments made by the
local site investigators at each CPET centre. The third
substudy will investigate the role of the 6 min walk test
(6MWT) for assessing preoperative functional capacity
and predicting postoperative outcome.46 This simple
and inexpensive exercise test may help stratify surgical
patients based on their performance on CPET.47 In a
subset of study participants, we will assess the ability of
the 6MWT to predict short-term postoperative quality of
recovery,48 medium-to-long term disability after
surgery,49 and performance on CPET.
ETHICS AND DISSEMINATION
The METS Study has received research ethics board
approval at all participating sites. The study poses
minimal additional risk to study participants.
Speciﬁcally, all CPET assessments are performed under
close medical supervision. In addition, prior data show
CPET to be very safe, with major complications occur-
ring in 8–13 per 100 000 tests, and death in 2–5 per
100 000 tests.30 It has an established role for assessing
patients with cardiopulmonary disease,30 and can be per-
formed safely in high-risk populations, such as indivi-
duals with pulmonary hypertension or small abdominal
aortic aneurysms.50 51 While the primary results (ie, VO2
peak and AT) of each CPET assessment remain con-
cealed until completion of the study, clinicians respon-
sible for study participants are informed of other
speciﬁc high-risk ﬁndings during exercise testing, such
as myocardial ischaemia or signiﬁcant new arrhythmias.
The results of the METS Study will be published in
peer-reviewed journals, in addition to being presented at
national and international conferences. We anticipate
these results to be published in 2017, after completion
of 1-year follow-up of all recruited participants. We will
also liaise with representatives of relevant clinical prac-
tice guideline organisations to ensure that the study
ﬁndings will help inform future recommendations for
perioperative care.3 4
CONCLUSIONS
By deﬁning the most accurate approaches for evaluating
preoperative cardiopulmonary ﬁtness, the results of the
METS Study will help clinicians to better identify high-
risk patients who would beneﬁt from preoperative opti-
misation, interventions, haemodynamic management,
closer postoperative surveillance or avoidance of surgery.
Furthermore, once patients with poor functional capacity
can be more accurately identiﬁed, opportunities will arise
for randomised controlled trials of interventions to
improve their outcomes, such as preoperative exercise
training programmes,52 perioperative haemodynamic
optimisation53 54 and enhanced postoperative care (eg,
hospitalist-surgeon co-management models).55–57 Thus,
the METS Study has the potential to substantially inform
and improve the care of the millions of individuals who
undergo major surgery worldwide every year.2
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